Lapatinib shows promise for inflammatory breast cancer.
D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000150:complications / Q000188:drug therapy*; D017322:Clinical Trials, Phase II as Topic; D005260:Female; D006801:Humans; D007249:Inflammation / Q000150:complications; D000077341:Lapatinib; D015337:Multicenter Studies as Topic; D011799:Quinazolines / Q000627:therapeutic use*
D000970:Antineoplastic Agents; D011799:Quinazolines; D000077341:Lapatinib